 | Up a level |
Journal Article
Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. 
ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J.
(2017).
Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center.
Oncol. Res. Treat., 40.
S. 137 - 139.
BASEL:
KARGER.
ISSN 2296-5262
Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Koleczko, S., Teixido, C., El Bairi, K., Morales Espinosa, D., Chatterjee, S., Rolfo, C., Koehler, J., Thommen, D., Ortiz-Cuaran, S., Abdulla, D. S. Y., Brandes, V., Bhaumik, S., Frizzera Borges Bognar, C. L., Calles, A., Holzem, A. and Wolf, J. (2017). An international platform representing expectations and experiences of young investigators in cancer research - [VI:N]. Oncol. Res. Treat., 40. S. 259 - 260. BASEL: KARGER. ISSN 2296-5262